Hypoactive Sexual Desire Disorder (HSDD): Causes, Diagnosis, and Treatment

What HSDD actually is, and what it is not

Hypoactive sexual desire disorder is a clinical diagnosis, not a synonym for "wanting sex less than my partner." Under DSM-5, it falls within female sexual interest/arousal disorder and requires that absent or reduced sexual interest, thoughts, or fantasies persist for at least 6 months and cause clinically significant personal distress to the woman herself. Distress is the criterion that separates a diagnosable disorder from normal variation in desire across relationships, life stages, and stress levels. A woman with low desire who is not bothered by it does not meet criteria for HSDD.

HSDD can be lifelong (present since sexual maturity) or acquired (developing after a period of typical desire), and generalized (present in all situations) or situational (tied to a specific partner or context). It is distinct from sexual aversion, which involves active fear or disgust toward sexual contact rather than an absence of interest.

Clinicians commonly use structured tools alongside the clinical interview: the Female Sexual Function Index (FSFI) to characterize desire, arousal, and related domains, and the Female Sexual Distress Scale-Revised (FSDS-R) to quantify distress. Published validation work on the FSFI has proposed a total-score cutoff in the mid-20s to separate women with and without sexual dysfunction, though exact sensitivity and specificity figures vary by study population and should be confirmed against the primary validation paper rather than treated as fixed.

A recent narrative review of HSDD etiology, diagnosis, and treatment frames the condition as multifactorial, arising from hormonal, neurobiological, and psychosocial contributors that interact rather than acting independently (Understanding Hypoactive Sexual Desire Disorder in Women, 2023, https://pubmed.ncbi.nlm.nih.gov/38161863/). That framing matters clinically: treating a single suspected cause in isolation, when two or three are present, is a common reason patients report partial or no benefit from a first treatment attempt.

Prevalence estimates for HSDD vary considerably depending on the survey instrument, the distress requirement applied, and the population studied. Broadly, published estimates place premenopausal HSDD with distress somewhere in the high single digits to low teens as a percentage, with figures rising in the postmenopausal population where declining estrogen and testosterone, sleep disruption, and genitourinary changes compound the picture. Readers should treat any single precise percentage with caution; exact figures depend heavily on methodology and should be checked against the specific survey cited before being repeated as a fixed statistic.

Why desire changes: hormonal, neurochemical, and psychosocial pathways

Hormonal pathways. Estrogen supports genital blood flow, lubrication, and clitoral sensitivity; testosterone acts on central dopaminergic circuits linked to sexual motivation. Serum testosterone in women declines gradually with age, independent of menopausal status, which means some premenopausal women develop desire problems from age-related androgen decline rather than menopause itself. Oral estrogen raises sex hormone-binding globulin (SHBG), which lowers free testosterone and can blunt desire even while relieving hot flashes and other menopausal symptoms; switching from oral to transdermal estradiol is a recognized way to reduce this effect. Certain progestins in combined contraceptives may also suppress desire in some women, while micronized progesterone is generally considered more desire-neutral, though individual response varies.

Neurochemical pathways. Sexual desire reflects a balance between excitatory signaling (dopamine, norepinephrine, melanocortin pathways) and inhibitory signaling (serotonin, opioid, and endocannabinoid pathways) in the central nervous system, a framework often described as the dual-control model. This helps explain why SSRIs, which increase serotonergic tone, are one of the most common reversible causes of reduced desire, and why an antidepressant with a different mechanism, such as bupropion, tends to carry a lower burden of sexual side effects.

Psychosocial pathways. Relationship dissatisfaction, unresolved conflict, a partner's own sexual dysfunction, history of sexual trauma, depression, anxiety, and body image concerns are each independently associated with low desire in the published literature. These factors are not a lesser or "soft" cause; in many studies of female sexual function, relationship quality is one of the strongest non-biological predictors of desire, and ignoring it in favor of a purely hormonal or pharmacological workup is a common source of treatment failure.

The practical point: HSDD rarely has one cause. A hormonal driver, a pain-related driver, a medication effect, and a psychosocial driver frequently coexist in the same patient, and each requires a different first move.

FDA-approved medications: what they treat and what they do not

Flibanserin (Addyi) is an oral tablet taken once daily at bedtime, approved by the FDA in 2015 specifically for acquired, generalized HSDD in premenopausal women. It is not a hormone; pharmacologically it acts on serotonin receptors (5-HT1A agonism, 5-HT2A antagonism) with weak dopaminergic activity, consistent with the excitation-inhibition model of desire. The bedtime dosing schedule is meant to reduce the risk of hypotension and syncope, its most clinically significant adverse effects. Alcohol within roughly 2 hours of a dose is contraindicated because of a pharmacodynamic interaction that can produce severe low blood pressure; in the US, flibanserin is dispensed only through a certified REMS (Risk Evaluation and Mitigation Strategy) program that requires prescriber and pharmacy certification. In placebo-controlled Phase 3 trials, flibanserin produced a modest but statistically significant increase in satisfying sexual events per month along with improved distress scores; the magnitude of benefit is real but small, and a meaningful share of trial participants did not experience a clinically noticeable difference. Readers who want exact trial numbers should consult flibanserin's FDA label and the published Phase 3 trial reports rather than rely on a single secondary summary, since reported effect sizes vary slightly by analysis.

Bremelanotide (Vyleesi) is a melanocortin receptor agonist self-administered as an on-demand subcutaneous injection roughly 45 minutes before anticipated sexual activity, used no more than once daily and generally limited in frequency per week per the label. It was FDA-approved in 2019 for the same population as flibanserin: premenopausal women with acquired, generalized HSDD. In its pivotal trials, bremelanotide improved desire and distress scores compared with placebo. Its most common side effect is transient nausea, reported by a substantial minority of users, and it produces a small, transient rise in blood pressure that makes it unsuitable for women with uncontrolled hypertension or significant cardiovascular disease.

Neither drug is FDA-approved for postmenopausal HSDD. Off-label use in postmenopausal women occurs and is discussed in specialty consensus guidance from the International Society for the Study of Women's Sexual Health (ISSWSH), but the pivotal trial evidence for both drugs comes from premenopausal populations, and effect sizes should not be assumed to transfer directly to postmenopausal women, whose desire problems more often coexist with genitourinary and hormonal changes not present in the trial population.

Testosterone therapy: substantial evidence, but no FDA-approved product for women

No testosterone product currently carries FDA approval for use in women in the United States. Despite that regulatory gap, transdermal testosterone has one of the larger evidence bases of any off-label HSDD intervention, and both the Endocrine Society and ISSWSH have published guidance addressing its use in postmenopausal women once other causes of low desire have been reasonably excluded.

A 2024 claims-database analysis of women prescribed systemic testosterone for HSDD documents real-world prescribing patterns, including who receives it and how therapy is typically structured, and is a useful reference for understanding how testosterone is actually being used outside of clinical trials rather than only in idealized guideline scenarios (Characteristics of systemic testosterone therapy for female hypoactive sexual desire disorder, 2024, https://pubmed.ncbi.nlm.nih.gov/38441520/). A separate 2024 clinical review of androgen excess and deficiency in women discusses the monitoring and safety considerations relevant to testosterone dosing in this population (Clinical management of androgen excess and defect in women, 2024, https://pubmed.ncbi.nlm.nih.gov/37953607/).

Because no approved product exists, prescribing in the US typically relies on compounded testosterone preparations, most often a low-concentration cream or gel applied to skin. Compounded preparations are not FDA-reviewed for consistency, purity, or potency the way an approved drug product is, which means dose delivered can vary between pharmacies and even between batches. Guideline-referenced practice aims to keep testosterone concentrations within the typical premenopausal female range, monitors levels several weeks after starting therapy and periodically thereafter, and watches for androgenic side effects such as acne, unwanted hair growth, or voice changes, which suggest a dose above the physiologic female range. Because compounded testosterone is off-label and unstandardized, the decision to use it should include an explicit conversation about this uncertainty, not just about expected benefit.

Genitourinary syndrome of menopause and its overlap with HSDD

Genitourinary syndrome of menopause (GSM) refers to vulvovaginal and urinary changes caused by estrogen deficiency: dryness, tissue thinning, reduced lubrication, dyspareunia, and urinary urgency. GSM and HSDD frequently coexist, and pain from GSM can create a learned aversion to sexual activity that suppresses desire independent of any hormonal or neurochemical driver. Treating GSM without also addressing a central desire deficit, or treating desire without addressing painful intercourse, tends to produce incomplete results.

First-line therapy for GSM is low-dose vaginal estrogen (cream, tablet, or ring) or vaginal prasterone (DHEA), both of which have a substantial trial base supporting relief of dryness and dyspareunia with minimal systemic absorption. Ospemifene, an oral selective estrogen receptor modulator, is an alternative for women who prefer a pill or cannot use vaginal products. None of these treat desire directly; they remove a physical barrier that may be suppressing it.

Dyspareunia and vaginismus: when pain, not desire, is the primary problem

Dyspareunia (painful intercourse) can be caused by GSM, endometriosis, interstitial cystitis, vulvodynia, pelvic inflammatory disease, or post-surgical scarring, and each cause points to a different treatment: vaginal estrogen for GSM-related pain, pelvic floor physical therapy or topical agents for vulvodynia, hormonal suppression or surgery for endometriosis. Because patients often do not volunteer pain as a symptom, a direct question about pain during or after intercourse belongs in every HSDD evaluation.

Vaginismus, classified under genito-pelvic pain/penetration disorder (GPPPD) in DSM-5, involves involuntary pelvic floor muscle contraction that makes penetration painful or impossible. Women with untreated vaginismus commonly develop secondary low desire as the brain associates arousal with anticipated pain. Pelvic floor physical therapy, using progressive dilators and manual techniques, is the primary treatment and is reported to resolve symptoms in the large majority of women who complete a full course, though completion rates and definitions of "resolution" vary between studies. Psychosexual therapy addresses the conditioned fear component. When vaginismus resolves, desire often improves without any additional pharmacological treatment, which is a strong argument for treating physical barriers before assuming a primary desire disorder is present.

Female orgasmic disorder is a separate diagnosis from HSDD

Female orgasmic disorder (FOD), persistent difficulty or inability to reach orgasm despite adequate stimulation, is distinct from HSDD even though the two can coexist. HSDD is a problem of desire generation; FOD is a problem of reaching climax once aroused. SSRIs are a leading pharmacological cause of acquired FOD, and switching to or augmenting with bupropion can partially restore orgasmic capacity in some women. Mindfulness-based approaches have reasonably strong trial support for FOD specifically. When a woman presents with both low desire and difficulty reaching orgasm, addressing the desire deficit first sometimes produces downstream improvement in orgasm, plausibly because more frequent, lower-pressure sexual activity reduces performance anxiety, though this sequencing is a clinical pattern rather than a proven algorithm.

A layered way to think about contributors

HSDD first-move decision guide. This is a way to organize the workup, not a substitute for individualized evaluation.

Do not start more than one new intervention at the same time. Staggering changes by roughly 8 to 12 weeks makes it possible to tell which intervention is actually responsible for improvement or side effects.

What the evidence does and does not establish

Established: HSDD is a recognized diagnosis requiring both low desire and distress. Flibanserin and bremelanotide are FDA-approved, with trial evidence specifically in premenopausal women, and each carries a distinct, well-characterized safety profile (hypotension/alcohol interaction for flibanserin; nausea and blood pressure effects for bremelanotide). SSRIs are a common and often reversible cause of reduced desire. Vaginal estrogen and prasterone are effective for GSM-related dryness and pain with minimal systemic absorption.

Plausible but not fully proven: That testosterone therapy, dosed to physiologic female range, meaningfully improves desire in postmenopausal women is supported by a substantial off-label evidence base and specialty society guidance, but no product is FDA-approved for this use in the US, and compounded formulations introduce dosing variability that trial data cannot fully account for. Combining flibanserin or testosterone with structured sex therapy is used clinically and has some small-study support, but has not been tested in large randomized trials against either therapy alone.

Not established: Precise prevalence figures, exact effect sizes (satisfying sexual events per month, standardized mean differences, or number-needed-to-treat), and diagnostic cutoff sensitivities cited in older secondary summaries should not be treated as fixed facts without checking the specific primary trial or guideline referenced, since these figures vary across analyses and populations. Universal testosterone screening for all women with low desire is not recommended by major endocrine guidance.

When to seek evaluation and when it is urgent

Evaluation is reasonable when low desire has lasted 6 months or more, causes personal distress, and is not fully explained by an obvious, temporary stressor. A gynecologist, endocrinologist, or sexual medicine specialist can screen for hormonal causes, medication effects, and physical conditions such as GSM, vaginismus, or dyspareunia. A certified sex therapist (the American Association of Sexuality Educators, Counselors and Therapists maintains a directory) is appropriate when relationship dysfunction, trauma history, or lifelong absence of desire with no identifiable biological cause appears to be the primary driver.

Sudden new pelvic pain, heavy or irregular bleeding, or symptoms suggesting a pituitary problem (visual changes, unexplained galactorrhea, severe headache) warrant prompt medical evaluation rather than a routine HSDD workup. Amenorrhea with low desire in a woman under 40 should prompt testing for premature ovarian insufficiency rather than an assumption that the cause is psychological.